Fasting insulin predicts cardiovascular mortality in pre-diabetes and remains elevated across type 2 diabetes: An NHANES 2007–2018 cohort analysis
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Cardiovascular disease accounts for most mortality in type 2 diabetes (T2D), yet treatment is anchored on glucose-derived metrics and fasting insulin is rarely measured. We tested whether fasting insulin carries cardiovascular-mortality information across the dysglycaemic spectrum and approaches non-diabetic levels with longer oral-therapy T2D duration.
Methods and Findings
We analysed six NHANES cycles [2007–2018] linked to National Death Index follow-up through 2019. Baseline characteristics were described in participants with complete kidney-function data: normoglycaemic (n = 2,913), pre-diabetes (n = 3,993), and oral-therapy T2D (n = 1,381). Survey-weighted Cox models used the covariate-complete mortality sample (pre-diabetes n = 4,019; oral-therapy T2D n = 1,387) and adjusted for age, sex, race/ethnicity, BMI, smoking, physical activity, education, poverty:income ratio, and insulin assay generation. Per +1 natural-log-unit fasting insulin, all-cause hazard ratios (HRs) were 1.69 (95% CI 1.14–2.50; P = 0.008) in pre-diabetes and 0.71 (0.51–0.98; P = 0.039) in oral-therapy T2D; cardiovascular HRs were 3.09 (1.69– 5.63; P < 0.001) and 0.50 (0.26–0.99; P = 0.046), respectively. Cancer mortality was not associated with fasting insulin. In oral-therapy T2D, geometric-mean fasting insulin remained 1.6- to 2.3-fold the normoglycaemic referent across duration bands. After BMI adjustment, fasting insulin declined during the first five years (−4.0%/year, P = 0.018) and was flat thereafter (−0.1%/year, P = 0.66).
Conclusions
Fasting insulin predicted cardiovascular mortality in pre-diabetes. In oral-therapy T2D, the inverse association was most consistent with survivor effects and accumulated renal and vascular damage. Fasting insulin remained above normoglycaemic levels throughout treated T2D.
